7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Yang X et al. | Effects of TGF-β1 on OPG/RANKL expression of cementoblasts and osteoblasts are similar without stress but different with mechanical compressive stress. | 2015 | ScientificWorldJournal | pmid:25685846 |
Zhang Q et al. | Local gene transfer of OPG prevents joint damage and disease progression in collagen-induced arthritis. | 2013 | ScientificWorldJournal | pmid:24222748 |
Teitelbaum SL | Bone resorption by osteoclasts. | 2000 | Science | pmid:10968780 |
Wickelgren I | Mining the genome for drugs. | 1999 | Science | pmid:10475849 |
Warren JT et al. | Manipulation of receptor oligomerization as a strategy to inhibit signaling by TNF superfamily members. | 2014 | Sci Signal | pmid:25140055 |
Zang L et al. | The effects of lung and prostate cancer bone metastasis on serum osteoprotegerin levels: a meta-analysis. | 2015 | Sci Rep | pmid:26671549 |
Schiro A et al. | Elevated levels of endothelial-derived microparticles, and serum CXCL9 and SCGF-β are associated with unstable asymptomatic carotid plaques. | 2015 | Sci Rep | pmid:26564003 |
Mizuno M et al. | Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease. | 2015 | Sci Rep | pmid:26561427 |
Nemeth ZK et al. | Serum osteoprotegerin is associated with pulse pressure in kidney transplant recipients. | 2015 | Sci Rep | pmid:26459001 |
Wang B et al. | Chondrocytes-Specific Expression of Osteoprotegerin Modulates Osteoclast Formation in Metaphyseal Bone. | 2015 | Sci Rep | pmid:26329493 |
Kao SY and Stankovic KM | Transactivation of human osteoprotegerin promoter by GATA-3. | 2015 | Sci Rep | pmid:26216189 |
Hope S et al. | Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. | 2013 | Schizophr. Res. | pmid:23403415 |
Dieset I et al. | Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein. | 2012 | Schizophr. Res. | pmid:22817875 |
Gehrke T et al. | Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. | 2003 | Scand. J. Rheumatol. | pmid:14690142 |
Spelling P et al. | Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker? | 2008 Nov-Dec | Scand. J. Rheumatol. | pmid:18802807 |
Sennels H et al. | Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. | 2008 Jul-Aug | Scand. J. Rheumatol. | pmid:18612923 |
Feuerherm AJ et al. | Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. | 2001 | Scand. J. Rheumatol. | pmid:11578019 |
Reenaers C et al. | Sensitivity of intestinal fibroblasts to TNF-related apoptosis-inducing ligand-mediated apoptosis in Crohn's disease. | 2008 | Scand. J. Gastroenterol. | pmid:18942021 |
Yilmaz Y et al. | Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. | 2010 | Scand. J. Clin. Lab. Invest. | pmid:20942739 |
Grauslund J et al. | Does osteoprotegerin relate to micro- and macrovascular complications in long-term type 1 diabetes? | 2010 | Scand. J. Clin. Lab. Invest. | pmid:20205614 |
Bjerre M et al. | Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial. | 2014 | Scand. J. Clin. Lab. Invest. | pmid:25026506 |
Sennels HP et al. | Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein. | 2007 | Scand. J. Clin. Lab. Invest. | pmid:17852826 |
Knudsen ST et al. | Plasma concentrations of osteoprotegerin during normo- and hyperglycaemic clamping. | 2007 | Scand. J. Clin. Lab. Invest. | pmid:17365993 |
Altinova AE et al. | Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes. | 2011 | Scand. J. Clin. Lab. Invest. | pmid:21486111 |
Muñoz-Calvo MT et al. | Maintained malnutrition produces a progressive decrease in (OPG)/RANKL ratio and leptin levels in patients with anorexia nervosa. | 2007 | Scand. J. Clin. Lab. Invest. | pmid:17558893 |
Hosbond SE et al. | Osteoprotegerin as a marker of atherosclerosis: a systematic update. | 2012 | Scand. Cardiovasc. J. | pmid:22506827 |
Stenman UH et al. | Prognostic value of serum markers for prostate cancer. | 2005 | Scand J Urol Nephrol Suppl | pmid:16019759 |
Mohamed GB and Abdel-Latif EA | Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome. | 2011 | Saudi J Kidney Dis Transpl | pmid:21912025 |
Takayanagi H | [Crosstalk between the immune and skeletal system]. | 2003 | Ryumachi | pmid:14598653 |
Gurban CV and Mederle O | The OPG/RANKL system and zinc ions are promoters of bone remodeling by osteoblast proliferation in postmenopausal osteoporosis. | 2011 | Rom J Morphol Embryol | pmid:22119834 |
Grigorie D et al. | Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. | 2003 | Rom J Intern Med | pmid:15526523 |
Grzegorzewska AE and MÅ‚ot M | Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15631341 |
Grzegorzewska AE and MÅ‚ot M | Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15631342 |
Naumnik W et al. | Serum levels of osteoprotegerin (OPG) and pro gastrin releasing peptide (ProGRP) during chemotherapy of lung cancer. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15638385 |
Fukagawa M et al. | [PTH and bone metabolism in chronic dialysis patients]. | 2001 | Rinsho Byori | pmid:11307321 |
Haynes DR et al. | Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. | 2001 | Rheumatology (Oxford) | pmid:11426018 |
Kim HR et al. | Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). | 2006 | Rheumatology (Oxford) | pmid:16567356 |
Corallini F et al. | The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis. | 2009 | Rheumatology (Oxford) | pmid:19168833 |
Smith MD | Comment on review on T cells in bone biology. | 2004 | Rheumatology (Oxford) | pmid:15448222 |
Pettit AR et al. | RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. | 2006 | Rheumatology (Oxford) | pmid:16490750 |
Bezerra MC et al. | Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. | 2005 | Rheumatology (Oxford) | pmid:16219645 |
Kwan Tat S et al. | Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. | 2009 | Rheumatology (Oxford) | pmid:19762475 |
Castellino G et al. | The tumour necrosis factor-related apoptosis-inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker? | 2010 | Rheumatology (Oxford) | pmid:20299382 |
Varsani H et al. | Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kappaB (RANK). | 2003 | Rheumatology (Oxford) | pmid:12649407 |
Engvall IL et al. | Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP--a possible mechanism for specific inhibition of radiological destruction. | 2013 | Rheumatology (Oxford) | pmid:23275387 |
Huang CH et al. | Osteoprotegerin genetic polymorphisms and age of symptom onset in ankylosing spondylitis. | 2011 | Rheumatology (Oxford) | pmid:20974615 |
Hofbauer LC et al. | Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. | 2006 | Rheumatology (Oxford) | pmid:16574701 |
Breland UM et al. | Inflammatory markers in patients with coronary artery disease with and without inflammatory rheumatic disease. | 2010 | Rheumatology (Oxford) | pmid:20231178 |
Haynes DR et al. | Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. | 2003 | Rheumatology (Oxford) | pmid:12509625 |
Harashima SI et al. | Osteoprotegerin and receptor activator of nuclear factor kappaB ligand expression in fibroblast-like synoviocytes from rheumatoid arthritis and osteoarthritis patients. | 2004 | Rheumatology (Oxford) | pmid:14963213 |
Xu S et al. | Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. | 2012 | Rheumatol. Int. | pmid:22057136 |
Skoumal M et al. | The imbalance between osteoprotegerin and cathepsin K in the serum of patients with longstanding rheumatoid arthritis. | 2008 | Rheumatol. Int. | pmid:18075741 |
Kanbe K et al. | Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis. | 2012 | Rheumatol. Int. | pmid:21789615 |
Oelzner P et al. | The balance between soluble receptors regulating IL-6 trans-signaling is predictive for the RANKL/osteoprotegerin ratio in postmenopausal women with rheumatoid arthritis. | 2012 | Rheumatol. Int. | pmid:20821212 |
Rooney T et al. | Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade. | 2010 | Rheumatol. Int. | pmid:19847430 |
Hein GE et al. | sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to non-destructive chronic arthritis. | 2008 | Rheumatol. Int. | pmid:18172654 |
Stupphann D et al. | Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis. | 2008 | Rheumatol. Int. | pmid:18369625 |
Yun HJ et al. | Adrenomedullin inhibits MAPK pathway-dependent rheumatoid synovial fibroblast-mediated osteoclastogenesis by IL-1 and TNF-alpha. | 2009 | Rheumatol. Int. | pmid:19116717 |
Agarwal S et al. | Synovial fluid RANKL and matrix metalloproteinase levels in enthesitis related arthritis subtype of juvenile idiopathic arthritis. | 2009 | Rheumatol. Int. | pmid:19052752 |
Zhou J et al. | Pulsed electromagnetic field stimulates osteoprotegerin and reduces RANKL expression in ovariectomized rats. | 2013 | Rheumatol. Int. | pmid:22948539 |
Keller KK et al. | SKG arthritis as a model for evaluating therapies in rheumatoid arthritis with special focus on bone changes. | 2013 | Rheumatol. Int. | pmid:22948540 |
Skoumal M et al. | Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. | 2005 | Rheumatol. Int. | pmid:15889303 |
Yao Y et al. | Combination of MTX and LEF attenuates inflammatory bone erosion by down-regulation of receptor activator of NF-kB ligand and interleukin-17 in type II collagen-induced arthritis rats. | 2013 | Rheumatol. Int. | pmid:23334376 |
Pamuk BO et al. | Evaluation of circulating endothelial biomarkers in familial Mediterranean fever. | 2013 | Rheumatol. Int. | pmid:23358733 |
Chen J et al. | OPG inhibits gene expression of RANK and CAII in mouse osteoclast-like cell. | 2012 | Rheumatol. Int. | pmid:22210270 |
Kwon SR et al. | Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. | 2012 | Rheumatol. Int. | pmid:21833531 |
Upton AR et al. | The expression of RANKL and OPG in the various grades of osteoarthritic cartilage. | 2012 | Rheumatol. Int. | pmid:21259010 |
Rosa-Rañal M et al. | [New paradigms in the regulation of bone metabolism]. | 2001 Jul-Aug | Rev. Invest. Clin. | pmid:11599485 |
Ciacli C et al. | [Bone turnover markers evaluation in psoriatic arthritis]. | 2008 Jul-Sep | Rev Med Chir Soc Med Nat Iasi | pmid:20201244 |
Collantes Estévez E and González DomÃnguez J | [Bone Paget's disease in the young adult]. | 2004 | Rev Clin Esp | pmid:15456600 |
Sasso GR et al. | Elevated serum osteoprotegerin levels in women: friend or foe? | 2015 Nov-Dec | Rev Assoc Med Bras (1992) | pmid:26841162 |
Riancho JA and Delgado-Calle J | [Osteoblast-osteoclast interaction mechanisms]. | 2011 | Reumatol Clin | pmid:21924211 |
Bogliolo L et al. | Biomarkers and prognostic stratification in psoriatic arthritis. | 2012 | Reumatismo | pmid:22690385 |
Bai P et al. | Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. | 2011 | Respir. Res. | pmid:22176920 |
Pobeha P et al. | Circulatory osteoprotegerin is related to osteoporosis of the hip in patients with COPD. | 2014 | Respir Med | pmid:24424018 |
Crisafulli A et al. | Osteoprotegerin and bone mineral density in hemodiafiltration patients. | 2005 | Ren Fail | pmid:16152990 |
Heymann MF et al. | OPG, RANK and RANK ligand expression in thyroid lesions. | 2008 | Regul. Pept. | pmid:18367263 |
Kadoglou NP et al. | Arterial stiffness and novel biomarkers in patients with abdominal aortic aneurysms. | 2012 | Regul. Pept. | pmid:22982141 |
Minenna G et al. | [RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report]. | 2005 | Recenti Prog Med | pmid:16229324 |
Kahl KG et al. | Bone mineral density, bone turnover, and osteoprotegerin in depressed women with and without borderline personality disorder. | 2006 Sep-Oct | Psychosom Med | pmid:17012519 |
Janda K et al. | [The relationship between advancement of secondary hyperparathyroidism and selected calcification parameters in peritoneal dialysis patients]. | 2012 | Prz. Lek. | pmid:23750431 |
Czyzewska-Buczyńska A et al. | [Assessment of osteopontin and osteoprotegerin levels in abdominal aortic aneurysm patients]. | 2013 | Prz. Lek. | pmid:24003660 |
Ziółkowska H and Roszkowska-Blaim M | [Osteoprotegerin and calcium-phosphorus metabolism parameters in children with chronic renal failure]. | 2006 | Prz. Lek. | pmid:16898492 |
Komosińska-Vassev K et al. | [Osteoporosis--pathophysiology and laboratory diagnostic methods]. | 2010 | Prz. Lek. | pmid:21387765 |
Liu Z et al. | Production of recombinant human osteoprotegrin from Trichoplusia ni cells and Bombyx mori larvae. | 2004 | Protein Pept. Lett. | pmid:15327363 |
Helo S et al. | Role of denosumab in prostate cancer. | 2012 | Prostate Cancer Prostatic Dis. | pmid:22370723 |
Quinn JE et al. | Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. | 2005 | Prostate Cancer Prostatic Dis. | pmid:15999121 |
Vandyke K et al. | Androgen decreases osteoprotegerin expression in prostate cancer cells. | 2007 | Prostate Cancer Prostatic Dis. | pmid:17189957 |
Armstrong AP et al. | RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. | 2008 | Prostate | pmid:18008334 |
Corey E et al. | Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. | 2002 | Prostate | pmid:11992617 |
Hesry V et al. | Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. | 2006 | Prostate | pmid:16541419 |
Burton DW et al. | Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. | 2005 | Prostate | pmid:15389781 |
Zheng Y et al. | Vitamin D deficiency promotes prostate cancer growth in bone. | 2011 | Prostate | pmid:21541977 |
Yonou H et al. | Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts. | 2007 | Prostate | pmid:17394194 |
Eaton CL et al. | Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. | 2004 | Prostate | pmid:15042606 |
Lin DL et al. | Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. | 2001 | Prostate | pmid:11351351 |
Poulsen RC et al. | Long chain polyunsaturated fatty acids alter membrane-bound RANK-L expression and osteoprotegerin secretion by MC3T3-E1 osteoblast-like cells. | 2008 | Prostaglandins Other Lipid Mediat. | pmid:18077200 |
Li X et al. | Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. | 2002 | Prostaglandins Other Lipid Mediat. | pmid:12013525 |
Wiercinska-Drapalo A et al. | Transforming growth factor beta1 and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients. | 2005 | Prostaglandins Other Lipid Mediat. | pmid:16303613 |
Yamamoto N et al. | Resveratrol reduces prostaglandin E1-stimulated osteoprotegerin synthesis in osteoblasts: suppression of stress-activated protein kinase/c-Jun N-terminal kinase. | Prostaglandins Other Lipid Mediat. | pmid:25677506 |